Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991277 | 0.93 | LMNA (0.32) | GRM2GRM3 | |
| SCHEMBL3620446 | 0.75 | MAPT (0.39) | — | |
| SCHEMBL3227341 | 0.74 | CYP1A2 (0.31) | — | |
| SCHEMBL4565810 | 0.73 | GRM4 (0.36) | GRM2GRM3 | |
| SCHEMBL4565697 | 0.73 | GRM4 (0.36) | GRM2GRM3 | |
| SCHEMBL29156987 | 0.73 | GRM2 (0.32) | GRM2GRM3 | |
| SCHEMBL3860387 | 0.73 | GRM2 (0.32) | GRM2GRM3 | |
| SCHEMBL7439240 | 0.73 | CYP1A2 (0.37) | — | |
| Hydrochloric Acid SCHEMBL21670172 | 0.71 | GRM2 (0.31) | GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL21670173 | 0.71 | GRM2 (0.31) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893579-B1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-05-01 | — | — | EP | disclosed |
| US-7816380-B2 | 1-hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2009-03-05 | — | — | US | disclosed |
| EP-1893579-A1 | 1-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006132837-A1 | l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062349-A1 | 1-Hydroxycycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, HRH4 | GRM2 768/4885GRM3 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.